Literature DB >> 1824642

The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

L Farnett1, C D Mulrow, W D Linn, C R Lucey, M R Tuley.   

Abstract

We critically appraised the medical literature to evaluate whether there is a point beyond which blood pressure reduction in hypertensive subjects is no longer beneficial and possibly even deleterious. Thirteen studies that stratified cardiovascular outcomes by level of achieved blood pressure in treated hypertensive subjects who had been followed up for at least 1 year were critiqued by four independent reviewers. Data addressing population, protocol, and methodological characteristics were evaluated. Studies did not show a consistent J-shaped relationship between treated blood pressure and stroke, but they did demonstrate a consistent J-shaped relationship for cardiac events and diastolic blood pressure. The beneficial therapeutic threshold point was 85 mm Hg. We conclude that low treated diastolic blood pressure levels, ie, below 85 mm Hg, are associated with increased risk of cardiac events.

Entities:  

Mesh:

Year:  1991        PMID: 1824642

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  80 in total

Review 1.  The j-point phenomenon in aggressive therapy of hypertension: new insights.

Authors:  Gurusher S Panjrath; Sameer Chaudhari; Franz H Messerli
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

2.  On redefining hypertension.

Authors:  Michel Accad; Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  The optimal blood pressure target for patients with coronary artery disease.

Authors:  Paolo Verdecchia; Fabio Angeli; Claudio Cavallini; Giovanni Mazzotta; Marta Garofoli; Paola Martire; Gianpaolo Reboldi
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

Review 4.  Blood pressure lowering in patients with diabetes--one level might not fit all.

Authors:  Rhonda M Cooper-DeHoff; Eric F Egelund; Carl J Pepine
Journal:  Nat Rev Cardiol       Date:  2010-11-16       Impact factor: 32.419

5.  Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing?

Authors:  Eve A Kerr; Michelle A Lucatorto; Rob Holleman; Mary M Hogan; Mandi L Klamerus; Timothy P Hofer
Journal:  Arch Intern Med       Date:  2012-06-25

6.  Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.

Authors:  Csaba P Kovesdy; Anthony J Bleyer; Miklos Z Molnar; Jennie Z Ma; John J Sim; William C Cushman; L Darryl Quarles; Kamyar Kalantar-Zadeh
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

7.  Relation of Diastolic Blood Pressure and Coronary Artery Calcium to Coronary Events and Outcomes (From the Multi-Ethnic Study of Atherosclerosis).

Authors:  Faisal Rahman; Mahmoud Al Rifai; Michael J Blaha; Khurram Nasir; Matthew J Budoff; Bruce M Psaty; Wendy S Post; Roger S Blumenthal; John W McEvoy
Journal:  Am J Cardiol       Date:  2017-08-08       Impact factor: 2.778

8.  Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study.

Authors:  Rebecca F Gottesman; Andrea L C Schneider; Marilyn Albert; Alvaro Alonso; Karen Bandeen-Roche; Laura Coker; Josef Coresh; David Knopman; Melinda C Power; Andreea Rawlings; A Richey Sharrett; Lisa M Wruck; Thomas H Mosley
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

Review 9.  The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.

Authors:  Yogini Ratnasabapathy; Carlene M M Lawes; Craig S Anderson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study.

Authors:  Farnaz Memarzadeh; Mei Ying-Lai; Jessica Chung; Stanley P Azen; Rohit Varma
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.